AGCT GmbH
Research - Marburg, Hesse, Germany
AGCT GmbH Employees
AGCT GmbH Senior Management
AGCT GmbH Details
Liquid biopsy cancer testingNon-invasive liquid biopsy tests are aimed at fundamentally changing cancer diagnostics and treatment. Existing technologies have performance limitations and narrow the potentials of liquid biopsy. What we doAGCT develops a groundbreaking PCR-based assay technology that will introduce an unmatched limit of detection for liquid biopsy cancer testing. At the same time our technology can be applied on standard laboratory equipment. AGCT's disruptive technologyAGCT's cyberPCR technology creates a new dimension of sensitivity and specificity in cancer detection. The proprietary technology already discriminates at the amplification step. Only mutant target sequences are amplified, permitting an unprecedented signal-noise ratio and a revolutionary level of rare mutant molecule detection for liquid biopsy.
AGCT GmbH Technologies
Load Balancers
Apache
CMS
WordPress.org
Fonts
Google Font API
Other
Mobile Friendly
CSS and JavaScript Libraries
Bootstrap Framework